Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Spero Therapeutics, Inc. (SPRO) had Stock-Based Compensation of $2.27M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$14.19M |
|
$-1.70M |
|
-- |
|
$14.19M |
|
$16.63M |
|
$-2.44M |
|
$0.74M |
|
$-1.70M |
|
$-1.70M |
|
$-1.70M |
|
$-1.70M |
|
$-1.70M |
|
$-1.70M |
|
$-2.44M |
|
$-2.44M |
|
56.03M |
|
56.03M |
|
$-0.03 |
|
$-0.03 |
|
| Balance Sheet Financials | |
$59.40M |
|
-- |
|
$2.72M |
|
$62.12M |
|
$14.95M |
|
-- |
|
$14.35M |
|
$29.29M |
|
$32.83M |
|
$32.83M |
|
$32.83M |
|
56.19M |
|
| Cash Flow Statement Financials | |
$-21.70M |
|
-- |
|
-- |
|
$52.89M |
|
$31.19M |
|
$-21.70M |
|
|
Stock-Based Compensation |
$2.27M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.97 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-17.22% |
|
-17.22% |
|
-- |
|
-11.98% |
|
-11.98% |
|
$-21.70M |
|
-- |
|
-- |
|
-- |
|
0.23 |
|
-- |
|
0.53 |
|
170.71 |
|
-5.18% |
|
-5.18% |
|
-2.74% |
|
-5.18% |
|
$0.58 |
|
$-0.39 |
|
$-0.39 |
|